Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage
Abstract
Background Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau 181 , total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage. Methods A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients. Results In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P<0.05 CS>pro-DLB; P<0.001 CS>DLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P<0.001 DLB groups
Domains
Life Sciences [q-bio]Eloi Magnin : Connect in order to contact the contributor
https://univ-fcomte.hal.science/hal-03630167
Submitted on : Monday, April 4, 2022-6:30:32 PM
Last modification on : Monday, April 4, 2022-6:30:33 PM
Dates and versions
Identifiers
- HAL Id : hal-03630167 , version 1
- DOI : 10.1136/jnnp-2017-316385
- PUBMED : 29321140
Cite
Olivier Bousiges, Stephanie Bombois, Susanna Schraen, David Wallon, Muriel Muraine Quillard, et al.. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89 (5), pp.467-475. ⟨10.1136/jnnp-2017-316385⟩. ⟨hal-03630167⟩
Collections
12
View
0
Download